- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04891640
Abbattimento biologico e cattura degli esiti dei bambini e della frequenza delle riacutizzazioni nella spondiloartrite giovanile (BACK-OFF JSpA)
Abbattimento biologico e cattura degli esiti dei bambini e della frequenza delle riacutizzazioni nella spondiloartrite giovanile (BACK-OFF JSpA)
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1E8
- The Hospital for Sick Children
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, Stati Uniti, 85006
- Phoenix Children's
-
-
California
-
Los Angeles, California, Stati Uniti, 90027
- Children's Hospital Los Angeles
-
Palo Alto, California, Stati Uniti, 94304
- Stanford University
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Children's Hospital of Colorado
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Nemours Children's Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20010
- Children's National Health System
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32827
- Nemours Children's Health
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Riley Hospital for Children at IU Health
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa Stead Family Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- University of Minnesota Masonic Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64108
- Children's Mercy Hospital
-
St Louis, Missouri, Stati Uniti, 63110
- St. Louis Children's Hospital
-
-
New York
-
New York, New York, Stati Uniti, 10021
- Hospital for Special Surgery
-
Queens, New York, Stati Uniti, 11040
- Cohen Children's Medical Center
-
-
Ohio
-
Akron, Ohio, Stati Uniti, 44302
- Akron Children's Hospital
-
Cincinnati, Ohio, Stati Uniti, 45229
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, Stati Uniti, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97227
- Randall Children's Hospital at Legacy Emanuel
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Stati Uniti, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- UT Southwestern Medical Center
-
Houston, Texas, Stati Uniti, 77030
- Texas Children's Hospital - Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Seattle Children's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Males or females age 8 to 21 years
-
Juvenile SpA diagnosis:
• Symptom onset before their 16th birthday:
o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype
OR;
• Symptom onset before their 18th birthday:
o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA
- Peripheral arthritis and enthesitis, or
- Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
- Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
- If peripheral arthritis is present, it should persist for at least 6 weeks.
-
Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses
-
Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician
-
English speaking or Spanish speaking
-
Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy
-
Interested and willing to de-escalate TNFi therapy
Exclusion Criteria:
1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: TNFi Standard Therapy
Continue fixed standard treatment (i.e., no change from current therapy) |
Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed. |
|
Sperimentale: TNFi fixed longer dosing intervals
Fixed longer dosing intervals of TNFi (i.e., increased time between doses) |
Participants randomly assigned to this arm will increase the time between TNFi medication doses.
|
|
Sperimentale: TNFi Therapy Withdrawal
Stop TNFi treatment |
Participants randomly assigned to this arm will stop TNFi medication. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Juvenile Spondyloarthritis (JSpA) flare
Lasso di tempo: 12 months
|
JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination. |
12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pain interference (as measured by the PROMIS short form)
Lasso di tempo: 12 months
|
Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10. |
12 months
|
Collaboratori e investigatori
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 21-018442
- : GRT-00001036 (Altro numero di sovvenzione/finanziamento: PCORI)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .